Lung cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• EGFR 301
• PD-L1 162
• PD-1 156
• KRAS 97
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• TROP2 14
• CTNNB1 0
• RAS 15
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

20 of 20+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, United States· until Sept 2031

• NIH NIEHS · F31

  PhosFate: Investigating Chemical Hazards, Community Exposures, and Health Risks from Phosphate Fertilizer Manufacturing

  University of South Florida· Tampa, United States· US$41,102 awarded in fiscal year 2026· until Sept 2028

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, United States· US$77,580 awarded in fiscal year 2026· until Sept 2028

• NIH NCI · R01

  Role of Allostatic Load in Immunotherapy Outcomes

  Ut Southwestern Medical Center· Dallas, United States· US$389,844 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$401,115 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1,463 running projects, newest first. Listed amounts together: US$846.0m + €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Terminated

  Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

  NCT06924606· Shanghai Junshi Bioscience Co., Ltd.· Updated 25 Sept 2026

  “The research and development strategy was adjusted, so the research was suspended”Registry text, quoted unchanged. Source

• Withdrawn

  Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

  NCT06943664· Roswell Park Cancer Institute· Updated 15 Sept 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· UNICANCER· Updated 3 Aug 2026

  “The study was terminated prematurely due to insufficient patient recruitment”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  ITIL-306 in Advanced Solid Tumors

  NCT05397093· Instil Bio· Updated 15 Apr 2026

  “The study was terminated early due to discontinuation of development of the investigational program”Registry text, quoted unchanged. Source

• Terminated

  A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

  NCT04432207· Imugene Limited· Updated 25 Mar 2026

  “Portfolio prioritization”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

  NCT06580938· Pfizer· Updated 23 Mar 2026

  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

  NCT06546553· Pfizer· Updated 23 Feb 2026

  “Study terminated as part of strategic considerations and not based on safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

  NCT02408861· National Cancer Institute (NCI)· Updated 21 Jan 2026

  “Inadequate accrual rate”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

  NCT06788912· Merck Sharp & Dohme LLC· Source

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Merck Sharp & Dohme LLC· Source

• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

  NCT04995523· AstraZeneca· Source

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· Merck Sharp & Dohme LLC· Source

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Merck Sharp & Dohme LLC· Source

• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

  NCT06780085· Merck Sharp & Dohme LLC· Source

• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Merck Sharp & Dohme LLC· Source

• A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

  NCT07217301· Takeda· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 618
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Integrated Whole-Genome and RNA Sequencing Analysis of FFPE Lung Cancer Samples: Feasibility and Pathological Validation.

  Pathol Int, Nov 2026

• Network-informed deconvolution of bulk immune gene co-expression reveals single-cell programs and spatial organization.

  Front Immunol, Sept 2026

• 5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

  Int J Mol Sci, Aug 2026

• Regulatory effects of smoking cessation on the cellular microenvironment and differentially expressed genes in precancerous lesions of pulmonary nodules in mice based on single-cell RNA sequencing and immune repertoire-sequencing.

  PLoS One, Aug 2026

• DeMixNB: deconvolution of sparse-count RNA sequencing data for tumor cells using embedded negative binomial distributions.

  Genome Biol, Aug 2026

• A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data.

  Sci Rep, Jul 2026

• PLNFGL: joint estimation of multi-condition gene networks from single-cell RNA-seq data.

  Bioinformatics, Jul 2026

• Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

  Semin Cancer Biol, Jun 2026

• ScQCenrich enables multi-metric quality control for single-cell RNA sequencing.

  Commun Biol, Jun 2026

• Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.

  Transl Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.